Hypoglycaemia is more frequent in type 2 diabetic patients with co-morbid vascular disease: An analysis of the DiaRegis registry

European Journal of Preventive Cardiology

Volumn 19, Issue 4, 2012, Pages 765-772

  Gitt, Anselm K ^a,b   Bramlage, Peter ^c   Binz, Christiane ^d   Krekler, Michael ^d   Plate, Tanja ^e   Deeg, Evelin ^b   Tschöpe, Diethelm ^f  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Institute for Cardiovascular Pharmacology and Epidemiology   (Germany)

^d BRISTOL MYERS SQUIBB   (United States)

^e ASTRAZENECA   (United Kingdom)

^f RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Hypoglycaemia; metformin; registry; sulfonylureas

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; GLITAZONE DERIVATIVE; GLUCOSE; GLYCOSIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; THIENOPYRIDINE DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; AGED; ANAMNESIS; ARTICLE; COMORBIDITY; DISEASE ASSOCIATION; DISEASE REGISTRY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; VASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEMICALLY INDUCED DISORDER; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; GERMANY; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; REGISTER; RISK; RISK ASSESSMENT; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; CHI-SQUARE DISTRIBUTION; COMORBIDITY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INCIDENCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; VASCULAR DISEASES;

EID: 84871490466     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711411104     Document Type: Article

References (22)

1. Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009 ; 52: 2288-2298
2. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008 ; 358: 2630-2633
3. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ. 2010 ; 340: b4909
4. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010 ; 363: 1410-1418
5. Currie CJ, Peters JR, Tynan A, Evans M, Heine RJ, Bracco OL, et al. Survival as a function of HbA(1c) in people with type 2 diabetes: A retrospective cohort study. Lancet. 2010 ; 375: 481-489
6. Bramlage P, Binz C, Gitt AK, Krekler M, Plate T, Deeg E, et al. Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline. Cardiovasc Diabetol. 2010 ; 9: 53-53
7. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008 ; 358: 580-591
8. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 ; 358: 2560-2572
9. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 ; 358: 2545-2559
10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352: 837-853
11. Kinsey J. Incidence and cause of death in shock therapy. Arch Neurol Psychiatry. 1941 ; 46: 55-58
12. Gilbert R, Goldzieher J. The mechanism and prevention of cardiovascular changes due to insulin. Ann Intern Med. 1946 ; 25: 928-940
13. Partamian JO, Bradley RF. Acute myocardial infarction in 258 cases of diabetes. Immediate mortality and five-year survival. N Engl J Med. 1965 ; 273: 455-461
14. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: A study based on continuous monitoring. Diabetes Care. 2003 ; 26: 1485-1489
15. Svensson AM, McGuire DK, Abrahamsson P, Dellborg M. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J. 2005 ; 26: 1255-1261
16. Fisman EZ, Motro M, Tenenbaum A, Leor J, Boyko V, Mandelzweig L, et al. Is hypoglycaemia a marker for increased long-term mortality risk in patients with coronary artery disease? An 8-year follow-up. Eur J Cardiovasc Prev Rehabil. 2004 ; 11: 135-143
17. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 ; 352: 854-865
18. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes. 1970 ; 19 (Suppl). 789-830
19. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Curr Atheroscler Rep. 2000 ; 2: 327-335
20. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol. 1998 ; 153: 17-23
21. Watanabe Y, Sunayama S, Shimada K, Sawano M, Hoshi S, Iwama Y, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb. 2000 ; 7: 159-163
22. Marx N, Mackman N, Schonbeck U, Yilmaz N, Hombach V, Libby P, et al. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation. 2001 ; 103: 213-219